Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting | ||
By: Nasdaq / GlobeNewswire - 08 Nov 2019 | Back to overview list |
|
CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that preclinical data from its oncology program, EDP1503, will be presented during the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 6–10, 2019 in National Harbor, Maryland. Details of the accepted abstract are as follows: The accepted abstract is listed below and available online on the SITC conference website: https://sitc.sitcancer.org/2019/abstracts/titles/index.php?filter=EDP1503. About Evelo Biosciences Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas. For more information, please visit www.evelobio.com. Contact Evelo Biosciences
|
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |